Find a Physician | How to Contribute | Contact Us | Clinical Trials
Search: 
Select a Cancer Type:
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Lymphoma: Non-Hodgkin's Lymphoma

A Phase 1b/2, Open-label Study to Evaluate the Safety and Tolerability of MEDI6469 in Combination with Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects with Selected Advanced Solid Tumors or Aggressive B-cell Lymphomas

The main purpose of this study is to determine the best dose of MEDI6469 that is safe and tolerable when given alone or in combination with tremelimumab, MEDI4736, or rituximab in subjects with either advanced solid tumors or diffuse large B-cell lymphoma (DLBCL).

Status: Accepting New Patients
Principal Investigator: Chae

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ibrutinib or Placebo in Combination With Rituximab in Subjects with Previously Treated Waldenstrom’s Macroglobulinemia

To evaluate the effect of the addition of ibrutinib to rituximab on PFS assessed by an IRC in subjects with previously treated WM.

Status: Accepting New Patients
Principal Investigator: Ma

A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma

The purpose of this study is to compare the effects, both good and/or bad, of Ibrutinib given in combination with Bendamustine and Rituximab to Bendamustine and Rituximab alone.

Status: Accepting New Patients
Principal Investigator: Petrich

Modular phase II study to link targeted therapy to patients with pathway activated tumors: Module 5 - LDE225 for patients with PTCH1 and SMO mutated tumors

Researchers want to know if LDE225 is safe and has beneficial effects in people who have different tumor types (cancer), and/or blood malignancies with a PTCH1 and/or SMO activated pathway. This pathway is thought to play a role in tumor cell growth as well as in the growth of new blood vessels, which supply the tumor with nutrients and oxygen.

Status: Accepting New Patients
Principal Investigator: Chae

A Phase I Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects with Relapsed/Refractory Diffuse Large B Cell and Transformed Follicular Lymphoma

The purpose of this study is to see how well the study drug, GSK2816126, works and how safe it is, as a treatment for diffuse large B-cell lymphoma (DLBCL) or transformed follicular lymphoma which has not responded or has returned after other treatments.

Status: Accepting New Patients
Principal Investigator: Winter

Modular Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 3 - MEK162 for Patients with RAS/RAF/MEK Activated Tumors Local

The purpose of this clinical trial is to study if MEK162 is safe and has beneficial effects in people who have different tumor types (cancer), and/or blood malignancies with a RAS/RAF/MEK activated pathway. This pathway is thought to play a role in tumor cell growth as well as in the growth of new blood vessels, which supply the tumor with nutrients and oxygen.

Status: Accepting New Patients
Principal Investigator: Chae

A Multicenter, Open-Label, Phase 2 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects with Relapsed/Refractory Marginal Zone Lymphoma

The purpose of this study is to evaluate how well ibrutinib treats marginal zone lymphoma (MZL).

Status: Accepting New Patients
Principal Investigator: Ma

Modular Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 4 - LGX818 for Patients with BRAFC600 Mutated Tumors

Researchers want to know if LGX818 is safe and has beneficial effects in people who have different tumor types (cancer), and/or blood malignancies with a BRAFV600 activated pathway. This pathway is thought to play a role in tumor cell growth as well as in the growth of new blood vessels, which supply the tumor with nutrients and oxygen.

Status: Accepting New Patients
Principal Investigator: Chae

Modular Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 2 - Dovitinib for Patients with Tumor Pathway Activations Inhibited by Dovitinib Including Tumors with Mutations or Translocations of FGFR, PDGFR, VEGF, CKIT, FLT3, CSFR1, TRK and RET

Researchers want to know if dovitinib (TKI258) is safe and has beneficial effects in people who have different tumor types (cancer) and/or blood malignancies whose disease progressed after standard treatment.

Status: Accepting New Patients
Principal Investigator: Chae

A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-cell Lymphoma (DLBCL)

Limited (or early) Stage Diffuse Large B-cell Lymphoma (DLBCL) is curable in many people, but some still relapse, and some develop side-effects after treatment. This study uses a radiologic test called PET/CT scan after initial standard chemotherapy (R-CHOP) to help individualize subsequent treatment in the hope of improving cure rates while decreasing side effects of treatment.

Status: Accepting New Patients
Principal Investigator: Petrich

A Phase 1B, Multi-Center, Open Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B cell Lymphoma

The main purpose of this study is to look at the safety and tolerability of combinations of three new drugs (CC-122, CC-223, and CC-292) being developed to treat diffuse large B cell lymphoma (DLBCL). The study aims to identify the highest doses tolerated by subjects, which will help guide future research studies. A drug called rituximab, which is already approved and used as therapy for this this disease, will also be part of this study.

Status: Accepting New Patients
Principal Investigator: Giles

An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-659 in Adult Patients with Advanced Solid Tumor and Lymphoma Malignancies

Two of the main purposes of this study are to determine the side effects and risks of TAK-659 and the highest dose of TAK-659 that can be given to patients daily without causing side effects and risks that are too severe.

Status: Accepting New Patients
Principal Investigator: Petrich

A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab as Frontline Therapy for Patients with CD30+ and/or EBV+ Lymphomas

The purpose of this study is to evaluate how safe and effective the combination of two different drugs (brentuximab vedotin and rituximab) is in patients with certain types of lymphoma.

Status: Accepting New Patients
Principal Investigator: Petrich

Extended Duration Varenicline for Smoking among Cancer Patients: A Clinical Trial

The main purpose of this research study is to compare 12 versus 24 weeks of varenicline treatment, also known as Chantix®, for smoking cessation.

Status: Accepting New Patients
Principal Investigator: Hitsman

A Phase 2 Proposal to Test the Efficacy and Tolerability of Bortezomib in Pulmonary Chronic GVHD

The purpose of a phase 2 study is to determine the efficacy, safety and tolerability of intravenous bortezomib in patients with pulmonary GVHD after allogeneic HSCT.

Status: Accepting New Patients
Principal Investigator: Jain

Multi-Center, Open-Label, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 or Investigator’s Choice in Subjects with Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

The main purpose of this study is to determine if KW-0761, an investigational drug (has not been approved by the U.S. food and Drug Administration [FDA]), will work against adult T-cell leukemia-lymphoma (ATL)that has failed to respond to other treatments, and to evaluate its side effects.

Status: Accepting New Patients
Principal Investigator: Petrich

Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine & Cytarabine with and without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System Lymphoma

This is a randomized investigational study is to determine the effects, good and/or bad, of the combination of low-dose whole brain radiation plus chemotherapy on PCNSL (Primary Central Nervous System Lymphoma) and tumor versus chemotherapy alone.

Status: Accepting New Patients
Principal Investigator: Raizer

Phase I/II Investigation of Temsirolimus Plus Lenalidomide in Relapsed Non-Hodgkin Lymphomas

The purpose of this study is threefold; first (phase I portion) to determine the safe dose of lenalidomide to be used with temsirolimus for the treatment of relapsed lymphomas (disease has come back or did not respond to treatment); second (phase II portion) to determine disease response (good and/or bad) to the study drugs; and third to determine the toxicity and safety of the treatment.

Status: Accepting New Patients
Principal Investigator: Petrich

last updated: Sat - November 01, 2014 - 08:00 AM

Fetching Clinical Trial!

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.